Ventana's diagnostic immunohistochemistry platform aims to analyze the expression level of certain tumor targets serving as biomarkers in clinical studies for patient selection. This will support the development of novel products in the field of oncology therapy and underscores Roche's commitment to personalized healthcare. This news comes on the heels of two separate companion diagnostic strategic collaborative agreements Ventana recently announced with Pfizer Inc. and Syndax Pharmaceuticals, Inc.
Under the terms of the Bayer agreement, Ventana will initially develop, manufacture and commercialize a companion diagnostic test for one of Bayer's ADCs. Over a period of five years, both parties may initiate further development projects to develop molecular diagnostic tests in support of additional targeted cancer therapy drugs. Financial terms of the agreement were not disclosed.
"At Ventana our mission is to improve the lives of all patients afflicted with cancer," said Mara G. Aspinall, President of Ventana Medical Systems, Inc. "We are pleased to be Bayer's partner of choice to facilitate the worldwide development of this ADC. As new biomarkers and diagnostic tests become increasingly available, they provide valuable information about potential positive recipients for these novel agents. Translating excellence in science into effective, targeted treatments for patients is at the core of Roche's scientific vision for 'Personalised Healthcare' (PHC), and it is our highest priority now and into the future."
"We are very excited to partner with Ventana to develop a companion diagnostic for one of our ADC projects," said Prof. Dr. Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare. "This constitutes another step for Bayer towards personalized medicine in cancer treatment as the selection of patients most likely to benefit from an ADC will increase the overall probability of therapeutic success for patients suffering from cancer."